Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.44 |
| ▸ | SLC2A3 | P11169 | 5/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 4/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839181 | 0.72 | CYP11B2 (0.48) | GRM1CYP11B2CYP11B1CYP17A1CYP19A1 | |
| SCHEMBL15839004 | 0.69 | CYP11B2 (0.48) | GRM1CYP11B2CYP11B1GAAKDM4E | |
| SCHEMBL6237143 | 0.69 | CYP11B2 (0.48) | SLC2A1SLC2A3SLC2A2GRM1CYP11B2 | |
| SCHEMBL15839017 | 0.67 | CYP11B2 (0.49) | GRM1CYP11B2CYP11B1CYP17A1CYP1A2 | |
| SCHEMBL9026151 | 0.66 | GRM1 (0.46) | GRM1CYP11B2CYP11B1CYP17A1CYP1A2 | |
| SCHEMBL28620635 | 0.66 | LMNA (0.43) | CYP11B2CYP11B1CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL25300648 | 0.64 | SMN1; SMN2 (0.45) | SLC2A1SLC2A3SLC2A2GRM1GAA | |
| SCHEMBL29404508 | 0.64 | SMN1; SMN2 (0.45) | SLC2A1SLC2A3SLC2A2GRM1GAA | |
| SCHEMBL28021141 | 0.64 | PTGS1 (0.46) | GRM1CYP11B2CYP1A2KDM4ENPC1 | |
| SCHEMBL30677333 | 0.64 | GRM1 (0.53) | SLC2A1SLC2A3SLC2A2GRM1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934144-B1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2934144-B1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9522141-B2 | Indazole compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522141-B2 | Indazole compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522141-B2 | Indazole compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2014099833-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP21A2, CYP11B1 | SLC2A1 3314/4885SLC2A3 2967/4885SLC2A2 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.